Antinuclear antibodies in women with recurrent early pregnancy loss: prevalence and impact on subsequent pregnancy outcome
Reproductive BioMedicine Online · 2026
DOI: 10.1016/j.rbmo.2025.105425 ↗Kurz gefasst
Fachartikel in der Zeitschrift Reproductive BioMedicine Online, 2026. Verfasst von Valerie Uvin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Brussels IVF, UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium. Electronic address: valerie.uvin@uzbrussel.be. Hauptthemen laut MEDLINE: Antibodies, Antinuclear, Abortion, Habitual, Pregnancy Outcome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Abstract (Originalsprache)
RESEARCH QUESTION: What is the prevalence of antinuclear antibodies (ANA) in women with recurrent early pregnancy loss (REPL), and do they affect subsequent pregnancy outcome? DESIGN: This single-centre, retrospective cohort study included 960 women consulting for REPL between January 2014 and December 2019. REPL was defined as ≥2 pregnancy losses before 10 weeks' gestation, including natural and autologous IVF/intracytoplasmic sperm injection pregnancies. ANA testing via indirect immunofluorescence on HEp-20-10 cells was part of routine evaluation. Confirmed systemic autoimmune diseases, uterine anomalies, parental chromosomal abnormalities, uncontrolled endocrine disorders and age ≥40 years were exclusion criteria. ANA prevalence and its association with subsequent pregnancy outcomes were assessed. The primary outcome was early pregnancy loss (EPL); secondary outcomes were biochemical pregnancy loss, clinical miscarriage and live birth rates. RESULTS: ANA screening of ≥1:80 was observed in 125/960 women (13.0%), comparable to the general population. No significant differences were seen in maternal age, body mass index, ethnicity or conception method between ANA-positive and ANA-negative women. The mean number of prior EPL was similar (2.7 versus 2.8, P = 0.06), but the percentage of women with thyroid antibodies was higher among ANA-positive women (21.6% versus 10.2%, P < 0.001). The subsequent EPL rate was similar (34.9% versus 40.5%, P = 0.33). Logistic regression showed no independent effect of ANA positivity for additional EPL (odds ratio 0.73, 95% CI 0.45-1.20, P = 0.22). Live birth rates were also similar (P = 0.50). CONCLUSIONS: ANA prevalence in women experiencing REPL was 13.0%, comparable to general population rates. ANA positivity did not negatively impact subsequent pregnancy outcomes. These findings do not support routine ANA testing in REPL or use of immunological add-ons based solely on ANA positivity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Brussels IVF, UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium. Electronic address: valerie.uvin@uzbrussel.be.
- Brussels IVF, UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium.
- Department of Rheumatology, UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium.
- Department of Clinical Biology, Laboratory of Hematology, UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium.
- Department of Public Health, Research Centre for Digital Medicine (REDM), Vrije Universiteit Brussel, Brussels, Belgium.
- Brussels IVF, UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium; Genetics, Reproduction and Development (GRAD Research Group), Vrije Universiteit Brussel, Brussels, Belgium.
Zitieren
APA
Uvin, V., Lerner, L., Melsens, K., Demeester, S., Buyl, R., Evers-Lebrun, C., De Brucker, M., Tournaye, H., Unuane, D., & Mackens, S. (2026). Antinuclear antibodies in women with recurrent early pregnancy loss: prevalence and impact on subsequent pregnancy outcome. Reproductive BioMedicine Online. https://doi.org/10.1016/j.rbmo.2025.105425
Vancouver
Uvin V, Lerner L, Melsens K, Demeester S, Buyl R, Evers-Lebrun C, et al. Antinuclear antibodies in women with recurrent early pregnancy loss: prevalence and impact on subsequent pregnancy outcome. Reproductive BioMedicine Online. 2026. doi:10.1016/j.rbmo.2025.105425
BibTeX
@article{Uvin2026,
author = {Uvin, Valerie and Lerner, Lieve and Melsens, Karin and Demeester, Simke and Buyl, Ronald and Evers-Lebrun, Corinne and De Brucker, Michael and Tournaye, Herman and Unuane, David and Mackens, Shari},
title = {Antinuclear antibodies in women with recurrent early pregnancy loss: prevalence and impact on subsequent pregnancy outcome},
journal = {Reproductive BioMedicine Online},
year = {2026},
doi = {10.1016/j.rbmo.2025.105425}
}
EUVIMED